Impact of Bridging Chemotherapy on Clinical Outcomes of CD19 CAR T Therapy in Relapse/Refractory Diffuse Large B- Cell Lymphoma in Real World Experience
Jérôme Paillassa, et al.
Intensity of bridging therapies (BT) was heterogeneous and closely related to tumor burden at enrollment. High intensity BT (HI chemotherapy+/-immunotherapy) and low intensity BT (LI, including monoclonal antibodies rituximab, brentuximab, dexamethasone, lenalidomide) showed no significant difference in efficacy, but a higher frequency of CRES was observed in the HI group.
